The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 19, 2019

Filed:

Jan. 27, 2017
Applicant:

SK Chemicals Co., Ltd., Gyeonggi-do, KR;

Inventors:

Hong Kee Kim, Gyeonggi-do, KR;

Kyu Ho Lee, Seoul, KR;

Seok Hyun Hong, Gyeonggi-do, KR;

Yong-kyu Kwak, Seoul, KR;

Ho Chul Shin, Gyeonggi-do, KR;

Hun-Teak Kim, Seoul, KR;

Assignee:

SK CHEMICALS CO., LTD., Gyeonggi-do, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/09 (2006.01); A61K 9/16 (2006.01); A61K 31/409 (2006.01); A61K 31/445 (2006.01); A61K 9/00 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 38/09 (2013.01); A61K 9/0019 (2013.01); A61K 9/16 (2013.01); A61K 9/5031 (2013.01); A61K 31/409 (2013.01); A61K 31/445 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition containing leuprolide acetate and having both immediate and sustained release properties and, more specifically, to a pharmaceutical composition in which, on the basis of the total weight of active ingredients, leuprolide as an immediate release preparation is contained in 0.001 wt % to 25 wt %; and leuprolide contained in microspheres of a sustained release preparation is contained in 75 wt % to 99.999 wt %. The pharmaceutical composition of the present invention is characterized by satisfying both a drug immediate release property so as to realize the prompt exposure to a sufficient amount of drug at the early stage for expression of medicinal effects and a drug sustained release property for four weeks or longer, and the pharmaceutical composition is effective in the prevention and treatment of sex hormone-dependent positive or malignant diseases.


Find Patent Forward Citations

Loading…